GlassScriptPhysician profile
Spring L Plihcik
NPI 1417949413
$5,421.50
in general payments reported to CMS, 2019-2025
20 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $172 · 2021: $1,108 · 2022: $1,224 · 2023: $1,015 · 2024: $889 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,918.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,292.90 | 2021-2025 | Tryptyr, Precision 1, Rocklatan |
| Johnson & Johnson Vision Care, INC. | $771.69 | 2020-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $390.84 | 2020-2025 | |
| Allergan, INC. | $360.35 | 2020-2022 | |
| Oyster Point Pharma, INC. | $317.77 | 2022-2024 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $314.90 | 2020-2023 | |
| Bausch & Lomb Americas INC. | $304.27 | 2022-2024 | Miebo, Xiidra, Vyzulta |
| Biotissue Holdings INC. | $249.64 | 2021-2025 | |
| Tarsus Pharmaceuticals, INC. | $219.44 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $169.09 | 2021-2024 | Oxervate |
| Horizon Therapeutics Plc | $158.45 | 2023 | Tepezza |
| Abbvie INC. | $157.26 | 2023-2025 | |
| Eyevance Pharmaceuticals LLC | $151.20 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $130.20 | 2021 | |
| Apellis Pharmaceuticals, INC. | $121.83 | 2024 | Syfovre |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $103.90 | 2024-2025 | Tepezza |
| Coopervision INC. | $83.68 | 2025 | Misight Contact Lens |
| Harrow Eye, LLC | $66.78 | 2024 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $29.99 | 2020-2021 | |
| Astellas Pharma US INC | $27.32 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spring Plihcik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.